Emerging treatment of atopic dermatitis.
Atopic dermatitis is a chronically relapsing eczematous disease of the skin. A wide range of therapeutic regimens has been used for atopic dermatitis. A better understanding of its pathogenesis will also lead to the development of novel approaches to treating this disease. This article reviews the recent advances in allergen-specific sublingual immunotherapy and therapy with antileukotriene drugs, probiotics, mycophenolate mofetil, leflunomide, and intermittent fluticasone propionate ointment, which the authors expect will be clinically useful therapies in the near future.
Hsu
Chih-Jung
CJ
Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China.
Wang
Li-Fang
LF
D000730:Androstadienes / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D003876:Dermatitis, Atopic / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods / Q000639:trends; D000068298:Fluticasone; D006634:Histamine H1 Antagonists / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D020024:Leukotriene Antagonists / Q000276:immunology / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000730:Androstadienes; D006634:Histamine H1 Antagonists; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D020024:Leukotriene Antagonists; D000068298:Fluticasone; D000077339:Leflunomide; D009173:Mycophenolic Acid